A Study of ARRY-334543 in Patients With Advanced Cancer

Key Inclusion Criteria:

• Histological or cytological evidence of malignancy.
• Patients with advanced solid tumors who are no longer candidates for standard therapy, have no standard therapy available, or choose not to pursue standard therapy.
• Cardiac ejection fraction ≥ 50% by echocardiogram (ECHO) or multiple gated acquisition (MUGA).
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2.
• Additional criteria exist.

Key Exclusion Criteria:

• Uncontrolled brain metastases (if a patient has brain metastases and is on steroids, the steroid dose must be stable for at least 30 days).
• Use of an investigational medication or device within 30 days prior to first dose of study drug.
• Major surgery within 30 days prior to first dose of study drug.
• Radiotherapy or chemotherapy within 28 days prior to first dose of study drug (not including palliative radiotherapy at focal sites).
• Active, uncontrolled infection requiring systemic antibiotic therapy or other serious underlying medical condition which would impair the ability of the patient to receive protocol treatment.
• Pregnancy or lactation.
• Known positive serology for the human immunodeficiency virus (HIV), 'active' hepatitis B and/or hepatitis C.
• Additional criteria exist.